Hyperuricemia and chronic deposition of monosodium urate crystals are the main cause of the gout. Urate lowering therapy (ULT) is the mainstay of chronic gout treatment. In this study, we evaluated demographic features and disease properties of the patients that would relate with the success of ULT. Sixty-six gout patients on pharmacologic ULT were enrolled in the study. Non-adherence to pharmacologic ULT was an exclusion criterium. Demographic and therapeutic features and co-illnesses and disease features of the patients were obtained during the study. Then, we compared these parameters between the patients with successful ULT and inadequate ULT. Adherence to diet was found different between the groups (OR, 7.00; CL%95 2.27 - 21.56). All other features including maximum allopurinol dosage were similar. We found that diet was the only factor that relate with success of ULT, while patients were on pharmacologic ULT. Non-adherence to both pharmacologic and non-pharmacologic measures is the main problem during ULT. Therefore, clinicians should emphasize the importance of all segments of ULT, including diet with informing patients during visits about the nature of disease and benefits of ULT.
References
1.
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases. 2017;76(1):29–42.
2.
Abhishek A, Doherty M. Education and non-pharmacological approaches for gout. Rheumatology. 2018;57(suppl_1):i51–8.
3.
Sheng F, Fang W, Zhang B, Sha Y, Zeng X. Adherence to gout management recommendations of Chinese patients. Medicine. 2017;96(45):e8532.
4.
Öztürk MA, Mercan R, Gök K, Onat AM, Kısacık B, Kimyon G, et al. The management of gout in different clinical specialties in Turkey: a patient-based survey. Clinical Rheumatology. 2016;35(12):3019–24.
5.
Nickolai B, Kiss C. Ernährungstherapie bei Gicht. Therapeutische Umschau. 2016;73(3):153–8.
6.
Zhang Y, Chen C, Choi H, Chaisson C, Hunter D, Niu J, et al. Purine-rich foods intake and recurrent gout attacks. Annals of the Rheumatic Diseases. 2012;71(9):1448–53.
7.
Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Annals of the Rheumatic Diseases. 2000;59(7):539–43.
8.
Tang O, Miller ER, Gelber AC, Choi HK, Appel LJ, Juraschek SP. DASH diet and change in serum uric acid over time. Clinical Rheumatology. 2017;36(6):1413–7.
9.
Khanna P, Hagerty D, Mischler R, Morlock R. FRI0397 Adherence to EULAR recommendations for the treatment of GOUT. Annals of the Rheumatic Diseases. 2012;71:448–9.
10.
Stamp LK, Merriman TR, Barclay ML, Singh JA, Roberts RL, Wright DFB, et al. Impaired response or insufficient dosage?—Examining the potential causes of “inadequate response” to allopurinol in the treatment of gout. Seminars in Arthritis and Rheumatism. 2014;44(2):170–4.
11.
Scheepers LEJM, van Onna M, Stehouwer CDA, Singh JA, Arts ICW, Boonen A. Medication adherence among patients with gout: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism. 2018;47(5):689–702.
12.
Dalbeth N, Merriman TR, Stamp LK. Gout. The Lancet. 2016;388(10055):2039–52.
13.
Abhishek A. New urate-lowing therapies. Current Opinion in Rheumatology. 2018;30(2):177–82.
14.
Guttmann A, Krasnokutsky S, Pillinger MH, Berhanu A. Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations. Therapeutic Advances in Drug Safety. 2017;8(12):379–88.
15.
Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Current Opinion in Rheumatology. 2010;22(2):165–72.
16.
Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD. Adherence: Comparison of Methods to Assess Medication Adherence and Classify Nonadherence. Annals of Pharmacotherapy. 2009;43(3):413–22.
17.
Neogi T, Jansen TLThA, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis & Rheumatology. 2015;67(10):2557–68.
18.
Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Medicine. 2017;15(1).
19.
Reyes AJ. Cardiovascular Drugs and Serum Uric Acid. Cardiovascular Drugs and Therapy. 2003;17(5–6):397–414.
20.
Merriman TR. An update on the genetic architecture of hyperuricemia and gout. Arthritis Research & Therapy. 17(1).
21.
Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care & Research. 2012;64(10):1431–46.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
